MARKET

NRIX

NRIX

Nurix Therapeutics, Inc.
NASDAQ
19.39
+0.37
+1.95%
After Hours: 19.39 0 0.00% 16:10 01/22 EST
OPEN
19.00
PREV CLOSE
19.02
HIGH
20.18
LOW
19.00
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
8.18
MARKET CAP
1.97B
P/E (TTM)
-6.5352
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Dexcom (DXCM)
TipRanks · 23h ago
Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), RegenXBio (RGNX) and Nurix Therapeutics (NRIX)
TipRanks · 1d ago
Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares
Reuters · 2d ago
Weekly Report: what happened at NRIX last week (0112-0116)?
Weekly Report · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)
TipRanks · 6d ago
Nurix Therapeutics: Why This Company Could Double In Value?
Seeking Alpha · 6d ago
Mizuho Securities Remains a Buy on Nurix Therapeutics (NRIX)
TipRanks · 01/14 07:15
More
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Webull offers Nurix Therapeutics Inc stock information, including NASDAQ: NRIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRIX stock methods without spending real money on the virtual paper trading platform.